Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829664 | 1.00 | TBXAS1 (0.59) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL2287581 | 1.00 | TBXAS1 (0.59) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL31016264 | 1.00 | TBXAS1 (0.59) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL1960855 | 0.98 | TBXAS1 (0.58) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL5512391 | 0.98 | TBXAS1 (0.56) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL1278389 | 0.91 | TBXAS1 (0.48) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL524907 | 0.81 | EGLN3 (0.54) | LMNATSHRFABP4FABP5MAPT | |
| SCHEMBL1960859 | 0.79 | TBXAS1 (0.40) | TBXAS1HDAC11HDAC3HDAC4HDAC1 | |
| SCHEMBL27458343 | 0.78 | TP53 (0.46) | TBXAS1LMNAMAPTALDH1A1 | |
| Sebacic Acid SCHEMBL27937400 | 0.78 | TSHR (0.86) | LMNATSHRNFKB1PMP22FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113373187-B | Nitrogen heterocyclic compound C 27 H 30 FNO 6 Is a method for enzymatic synthesis of (a) | 江苏阿尔法药业股份有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-113373187-A | Nitrogen heterocyclic compound C27H30FNO6Enzyme-catalyzed synthesis method of | 江苏阿尔法药业股份有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-100471836-C | Crystalline forms VI and VII of atorvastatin calcium | REDDYS LAB LTD DR (IN) | 2009-03-25 | — | — | CN | claimed |
| EP-1625223-A2 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STATIN INTERMEDIATES | Diversa Corporation (US) | 2006-02-15 | — | — | EP | claimed |
| EP-1507813-A4 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LAB LTD (IN) | 2005-11-23 | — | — | EP | claimed |
| WO-2005033078-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM | BIOCON LIMITED (IN) | 2005-04-14 | — | — | WO | claimed |
| EP-1507813-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | Ranbaxy Laboratories Limited (IN) | 2005-02-23 | — | — | EP | claimed |
| CN-1537098-A | Crystalline forms VI and VII of atorvastatin calcium | ʵ | 2004-10-13 | — | — | CN | claimed |
| WO-2004027075-A2 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STAIN INTERMEDIATES | DIVERSA CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| EP-1385501-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2003097714-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2003-11-27 | — | — | WO | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| CN-1087288-C | Crystalline [R-(R',R')]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(5-methylethyl)-3-phenyl-4-(phenylamino) carbonyl]-1H-pyrole-1-heptanoic acid hemi calcium salt (atorvastatin) | WARNER LAMBERT CO (US) | 2002-07-10 | — | — | CN | claimed |
| CN-1190955-A | Crystalline [R-(R',R')]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(5-methylethyl)-3-phenyl-4-(phenylamino) carbonyl]-1H-pyrole-1-heptanoic acid hemi calcium salt (atorvastatin) | WARMER LAMBERT CO (US) | 1998-08-19 | — | — | CN | claimed |
| EP-0698609-A1 | Alpha-phosphorus substituted sulfinate derivatives as squalene synthetase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-02-28 | — | — | EP | claimed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| CN-1089614-A | Alpha-phosphonosulfonate squalene synthetase inhibitors and method | SQUIBB & SONS INC (US) | 1994-07-20 | — | — | CN | claimed |
| EP-0409281-A1 | (R-(R*R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)-carbonyl)-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof | WARNER-LAMBERT COMPANY (US) | 1991-01-23 | — | — | EP | claimed |
| CN-117747034-A | System and method for over-the-counter dispensing statin drugs | 阿斯利康(英国)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117711550-A | System and method for over-the-counter dispensing statin drugs | 阿斯利康(英国)有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-110612575-B | System and method for over-the-counter dispensing statin drugs | 阿斯利康(英国)有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-113373187-B | Nitrogen heterocyclic compound C 27 H 30 FNO 6 Is a method for enzymatic synthesis of (a) | 江苏阿尔法药业股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-113373187-B | Nitrogen heterocyclic compound C 27 H 30 FNO 6 Is a method for enzymatic synthesis of (a) | 江苏阿尔法药业股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110668990-B | Crystallization method for preparing high-purity monodisperse I crystal form atorvastatin calcium in single kettle | 天津大学 | 2022-04-19 | — | — | CN | disclosed |
| CN-110563628-B | Crystallization method for preparing high-purity and monodisperse I crystal form atorvastatin calcium by double kettles | 北京嘉林药业股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-113373187-A | Nitrogen heterocyclic compound C27H30FNO6Enzyme-catalyzed synthesis method of | 江苏阿尔法药业股份有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-113373187-A | Nitrogen heterocyclic compound C27H30FNO6Enzyme-catalyzed synthesis method of | 江苏阿尔法药业股份有限公司 | 2021-09-10 | — | — | CN | disclosed |
| WO-2020016903-A1 | AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF PYRROLE DERIVATIVES WITH IMPROVED IMPURITY PROFILE & MINIMISATION OF UNIT OPERATIONS. | ARCH PHARMALABS LIMITED (IN) | 2020-01-23 | — | — | WO | disclosed |
| CN-109771650-A | The composition being made of rush histamine release object and two substituted biphenyl derivatives | 黄泳华 | 2019-05-21 | — | — | CN | disclosed |
| WO-2017060885-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2017-04-13 | — | — | WO | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| EP-1470258-B1 | COMPOSITION AND ITS USE FOR IMPARTING WATER REPELLENCY TO LEATHER OR FURSKINS, TEXTILES AND OTHER FIBROUS MATERIALS | TFL LEDERTECHNIK GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8460708-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-06-11 | — | — | US | disclosed |
| US-20130012683-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8303973-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120252905-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG | 2012-10-04 | — | — | US | disclosed |
| EP-1708694-B1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INT AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120052040-A1 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2012-03-01 | — | — | US | disclosed |
| US-20120041481-A1 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20120039980-A1 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2012-02-16 | — | — | US | disclosed |
| US-8067031-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2011-11-29 | — | — | US | disclosed |
| EP-2373609-A1 | USE OF AMPHIPHILIC COMPOUNDS FOR CONTROLLED CRYSTALLIZATION OF STATINS AND STATIN INTERMEDIATES | KRKA, D.D., Novo Mesto (SI) | 2011-10-12 | — | — | EP | disclosed |
| CN-1946687-B | Polymorphic substance of atorvastatin tert-butyl ester and application of polymorphic substance as intermediate in preparation of atorvastatin | KRKA TOVARNA ZDRAVIL D D NOVO MESTO | 2011-09-28 | — | — | CN | disclosed |
| EP-2328563-A1 | SOLUBILITY ENHANCING PHARMACEUTICAL FORMULATION | Bilgic, Mahmut (TR) | 2011-06-08 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2011002422-A2 | SOLUBILITY ENHANCING PHARMACEUTICAL FORMULATION | MAHMUT BILGIC (TR) | 2011-01-06 | — | — | WO | disclosed |
| US-20100268288-A1 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010069593-A1 | USE OF AMPHIPHILIC COMPOUNDS FOR CONTROLLED CRYSTALLIZATION OF STATINS AND STATIN INTERMEDIATES | KRKA, D. D., NOVO MESTO (SI) | 2010-06-24 | — | — | WO | disclosed |
| EP-2192920-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF RADIATION-INDUCED FIBROSIS | Virginia Commonwealth University Intellectual Property Foundation (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-2181704-A2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021608-A1 | SOLUBILITY ENHANCING PHARMACEUTICAL FORMULATION | BILGIC MAHMUT (TR) | 2010-02-25 | — | — | WO | disclosed |
| EP-1594459-B1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INT AG (CH) | 2010-02-17 | — | — | EP | disclosed |
| US-7645888-B2 | Process for the production of amorphous atorvastatin calcium | BIOCON LIMITED (IN) | 2010-01-12 | — | — | US | disclosed |
| EP-2132171-A1 | NOVEL CRYSTAL FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES | Dong-A Pharm.Co., Ltd. (KR) | 2009-12-16 | — | — | EP | disclosed |
| CN-101560177-A | Preparation method of atorvastatin calcium | BEIJING WANQUAN SUNSHINE MEDIC (CN) | 2009-10-21 | — | — | CN | disclosed |
| CN-101538238-A | Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin | KRKA TOVARNA ZDRAVIL D D NOVO | 2009-09-23 | — | — | CN | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-1274401-A4 | STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING 7-SUBSTITUTED-3,5-DIHYDROXYHEPTANOIC ACIDS OR 7-SUBSTITUTED-3,5-DIHYDROXYHEPTENOIC ACIDS | TEVA PHARMA (IL) | 2009-07-22 | — | — | EP | disclosed |
| US-20090171099-A1 | PROCESS FOR THE PRODUCTION OF AMORPHOUS ATORVASTATIN CALCIUM | BIOCON LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-2066788-A2 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | Codexis, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| CN-101420991-A | Polymer compositions and methods for their use | ANGIOTECH INT AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| CN-100482645-C | Methods of reversing and preventing cardiovascular pathologies | ATHEROGENICS INC (US) | 2009-04-29 | — | — | CN | disclosed |
| CN-101420970-A | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INT AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| EP-1784389-A4 | PROCESS FOR ATORVASTATIN CALCIUM AMORPHOUS | BIOCON LTD (IN) | 2009-03-25 | — | — | EP | disclosed |
| CN-100471836-C | Crystalline forms VI and VII of atorvastatin calcium | REDDYS LAB LTD DR (IN) | 2009-03-25 | — | — | CN | disclosed |
| WO-2009026428-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF RADIATION-INDUCED FIBROSIS | VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ANGIOTECH PHARMACEUTICALS(US),INC. (US) | 2008-12-18 | — | — | US | disclosed |
| CN-101318923-A | Crystalline forms of 'r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'(phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid | WARNER LAMBERT CO (US) | 2008-12-10 | — | — | CN | disclosed |
| WO-2008108572-A1 | NOVEL CRYSTAL FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES | DONG-A PHARM. CO., LTD. (KR) | 2008-09-12 | — | — | WO | disclosed |
| US-7371895-B2 | Salt forms of poorly soluble probucol esters and ethers | ATHEROGENICS, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7361772-B2 | Process for the production of atorvastatin calcium | BIOCON LIMITED (IN) | 2008-04-22 | — | — | US | disclosed |
| WO-2008042876-A2 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | CODEXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| CN-101094613-A | Medical implant and anti-scarring agent | ANGIOTECH INT AG (CH) | 2007-12-26 | — | — | CN | disclosed |
| WO-2007131528-A1 | PROCESS FOR PREPARING C5 INTERMEDIATES AND THEIR USE IN THE PREPARATION OF N-SUBSTITUTED PYRROLE DERIVATIVES | RATIOPHARM GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
| EP-1853249-A2 | A STABLE PHARMACEUTICAL COMPOSITION COMPRISING A FIXED DOSE COMBINATION OF FENOFIBRATE AND AN HMG-COA REDUCTASE INHIBITOR | LifeCycle Pharma A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007107276-A2 | PROCESS FOR PREPARING C7 INTERMEDIATES AND THEIR USE IN THE PREPARATION OF N-SUBSTITUTED PYRROLE DERIVATIVES | RATIOPHARM GMBH (DE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007099552-A2 | NOVEL CRYSTALLINE FORM OF ATOVASTATIN HEMI-MAGNESIUM | MATRIX LABARATORIES LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| CN-1330644-C | Hydrolysis of [ R with calcium hydroxide*,R*)]-2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3-phenyl-4- [ (phenylamino) carbonyl]-1H-pyrrole-1-heptanoate | TEVA PHARMA (IL) | 2007-08-08 | — | — | CN | disclosed |
| US-7250456-B2 | Composition and its use for imparting water repellency to leather or furskins, textiles and other fibrous materials | TFL LEDERTECHNIK GMBH (DE) | 2007-07-31 | — | — | US | disclosed |
| EP-1796602-A2 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | Angiotech Pharmaceuticals (US), Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1784389-A1 | PROCESS FOR ATORVASTATIN CALCIUM AMORPHOUS | Biocon Limited (IN) | 2007-05-16 | — | — | EP | disclosed |
| EP-1771412-A2 | CRYSTALLINE FORMS OF [R-(R*)]-2-(4-FLUOROPHENYL)-BET A,GAMMA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPT ANOIC ACID CALCIUM SALT (2:1) | Warner-Lambert Company LLC (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1946687-A | Polymorphic substance of atorvastatin tert-butyl ester and application of polymorphic substance as intermediate in preparation of atorvastatin | KRKA TOVARNA ZDRAVIL D D NOVO (SI) | 2007-04-11 | — | — | CN | disclosed |
| US-7183317-B2 | Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality | ATHEROGENICS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1745020-A2 | SALT FORMS OF ATORVASTATIN | Pfizer Products Incorporated (US) | 2007-01-24 | — | — | EP | disclosed |
| CN-1897930-A | Compositions and methods for treating contracture | ANGIOTECH INT AG (CH) | 2007-01-17 | — | — | CN | disclosed |
| US-20060282123-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2006-12-14 | — | — | US | disclosed |
| CN-1878514-A | Soft tissue implants and anti-scarring agents | ANGIOTECH INT AG (CH) | 2006-12-13 | — | — | CN | disclosed |
| CN-1878594-A | Electrical devices and anti-scarring agents | ANGIOTECH INT AG (CH) | 2006-12-13 | — | — | CN | disclosed |
| CN-1852894-A | [R－(R*, R*)]-2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3-phenyl-4- [ (phenylamino) carbonyl]Crystalline forms of -1H-pyrrole-1-heptanoic acid | WARNER LAMBERT CO (US) | 2006-10-25 | — | — | CN | disclosed |
| WO-2006084474-A2 | A STABLE PHARMACEUTICAL COMPOSITION COMPRISING A FIXED DOSE COMBINATION OF FENOFIBRATE AND AN HMG-COA REDUCTASE INHIBITOR | LIFECYCLE PHARMA A/S (DK) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006083260-A2 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-08-10 | — | — | WO | disclosed |
| EP-1684819-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| WO-2006078282-A2 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060147492-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2006-07-06 | — | — | US | disclosed |
| WO-2006066823-A1 | PROCESS FOR PREPARING PYRROLE DERIVATIVES AND INTERMEDIATES | RATIOPHARM GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1551791-A4 | NOVEL SALT FORMS OF POORLY SOLUBLE PROBUCOL ESTERS AND ETHERS | ATHEROGENICS INC (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006048893-A2 | A PROCESS FOR SYNTHESIS OF LARGE PARTICLE SIZE STATIN COMPOUNDS | MOREPEN LABORATORIES LIMITED (IN) | 2006-05-11 | — | — | WO | disclosed |
| EP-1653865-A2 | ANASTOMOTIC CONNECTOR DEVICES | ANGIOTECH INTERNATIONAL AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| US-20060084816-A1 | Process for the production of atorvastatin calcium | BIOCON LIMITED (IN) | 2006-04-20 | — | — | US | disclosed |
| US-20060079713-A1 | Novel salt forms of poorly soluble probucol esters and ethers | ATHEROGENICS, INC. | 2006-04-13 | — | — | US | disclosed |
| CN-1756530-A | Drug delivery from rapid gelling polymer compositions | ANGIOTECH INTERNAT GMBH (CH) | 2006-04-05 | — | — | CN | disclosed |
| CN-1756571-A | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNAT GMBH (CH) | 2006-04-05 | — | — | CN | disclosed |
| WO-2006034128-A2 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH BIOMATERIALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006021969-A1 | PROCESS FOR ATORVASTATIN CALCIUM AMORPHOUS | BIOCON LIMITED (IN) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006011041-A2 | CRYSTALLINE FORMS OF (R-(R*))-2-(4-FLUOROPHENYL)-BETA, GAMMA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-1H-PYRROLE-1-HEPT ANOIC ACID CALCIUM SALT (2:1) | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050281883-A1 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2005-12-22 | — | — | US | disclosed |
| EP-1507813-A4 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LAB LTD (IN) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005105738-A2 | SALT FORMS OF ATORVASTATIN | PFIZER PRODUCTS INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-6960683-B2 | Salt forms of poorly soluble probucol esters and ethers | ATHEROGENICS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050209664-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20050209666-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20050209665-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20050208095-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-22 | — | — | US | disclosed |
| EP-1577297-A1 | Process for the production of atorvastatin calcium in amorphous form | RANBAXY LABORATORIES, LTD. (IN) | 2005-09-21 | — | — | EP | disclosed |
| US-20050203635-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-15 | — | — | US | disclosed |
| US-20050196421-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-08 | — | — | US | disclosed |
| US-20050191331-A1 | e.g. central nervous system shunt; antiscarring agent such as an angiogenesis inhibitor to inhibit scarring between the implant and a host | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-01 | — | — | US | disclosed |
| US-20050192647-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-01 | — | — | US | disclosed |
| US-20050187600-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050186261-A1 | Compositions and methods for treating contracture | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050186245-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050186239-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050186244-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050183728-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050186246-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050183731-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050187639-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050181011-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182463-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050181977-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182496-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182467-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182450-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050181009-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050181008-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050181005-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050178395-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050181010-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182469-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050178396-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050182468-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050175703-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050175664-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050175663-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050175665-A1 | In combination with antiscarring, antifibrotic, and antiinflammatory agents for preventing surgical adhesions, and cartilage loss; hypertrophic scars, keloids, arthritis, vascular disease; injection or topical administration | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050177225-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050169961-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-04 | — | — | US | disclosed |
| US-20050169960-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-04 | — | — | US | disclosed |
| US-20050165488-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (SE) | 2005-07-28 | — | — | US | disclosed |
| US-20050158356-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-21 | — | — | US | disclosed |
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050154374-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050152948-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050152941-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050152944-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050152947-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| EP-1551791-A1 | NOVEL SALT FORMS OF POORLY SOLUBLE PROBUCOL ESTERS AND ETHERS | Atherogenics, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050148702-A1 | Composition and its use for imparting water repellency to leather or furskins, textiles and other fibrous materials | TFL LEDERTECHNIK GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20050149158-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050143817-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| EP-1451138-A4 | METHODS OF REVERSING AND PREVENTING CARDIOVASCULAR PATHOLOGIES | ATHEROGENICS INC (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005051452-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005046516-A2 | MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| CN-1612855-A | Method for reversing and preventing cardiovascular disease | ATHEROGENICS INC (US) | 2005-05-04 | — | — | CN | disclosed |
| US-6881860-B2 | Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality | ATHEROGENICS, INC. (US) | 2005-04-19 | — | — | US | disclosed |
| WO-2005033078-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM | BIOCON LIMITED (IN) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065121-A1 | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters | SIKORSKI JAMES A (US) | 2005-03-24 | — | — | US | disclosed |
| WO-2005018683-A2 | ANASTOMOTIC CONNECTOR DEVICES | ANGIOTECH INTERNATIONAL AG (CH) | 2005-03-03 | — | — | WO | disclosed |
| EP-1507813-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | Ranbaxy Laboratories Limited (IN) | 2005-02-23 | — | — | EP | disclosed |
| CN-1561341-A | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide | TEVA PHARMA (IL) | 2005-01-05 | — | — | CN | disclosed |
| US-20040266879-A1 | Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality | ATHEROGENICS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1470258-A1 | COMPOSITION AND ITS USE FOR IMPARTING WATER REPELLENCY TO LEATHER OR FURSKINS, TEXTILES AND OTHER FIBROUS MATERIALS | TFL Ledertechnik GmbH (DE) | 2004-10-27 | — | — | EP | disclosed |
| CN-1537098-A | Crystalline forms VI and VII of atorvastatin calcium | ʵ | 2004-10-13 | — | — | CN | disclosed |
| EP-1451138-A2 | METHODS OF REVERSING AND PREVENTING CARDIOVASCULAR PATHOLOGIES | Atherogenics, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| CN-1157374-C | Process for preparation of amorphous atorvastatin calcium | ����˹ҩ�﹤�� | 2004-07-14 | — | — | CN | disclosed |
| US-20040110803-A1 | Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels | SAMFORD UNIVERSITY | 2004-06-10 | — | — | US | disclosed |
| US-20040082807-A1 | Novel salt forms of poorly soluble probucol esters and ethers | CRABTREE ACQUISITION CO, LLC | 2004-04-29 | — | — | US | disclosed |
| WO-2004024094-A2 | METHODS AND COMPOSITONS FOR THE USE OF D-MALIC ACID TO DECREASE SERUM TRIGLYCERIDE, CHOLESTEROL, AND LIPOPROTEIN LEVELS | SAMFORD UNIVERSITY (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1385501-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2004007423-A1 | NOVEL SALT FORMS OF POORLY SOLUBLE PROBUCOL ESTERS AND ETHERS | ATHEROGENICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003097714-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2003-11-27 | — | — | WO | disclosed |
| US-20030181520-A1 | Methods of reversing and preventing cardiovascular pathologies | ATHEROGENICS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003064707-A1 | COMPOSITIONS AND ITS USE FOR IMPARTING WATER REPELLENCY TO LEATHER OR FURSKINS, TEXTILES AND OTHER FIBROUS MATERIALS | TFL LEDERTECHNIK GMBH (DE) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003039352-A2 | METHODS OF REVERSING AND PREVENTING CARDIOVASCULAR PATHOLOGIES | ATHEROGENICS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| US-20030064967-A1 | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters | ATHEROGENICS, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20030032578-A1 | Antifungal and antiparasitic compounds | UNITED STATES GOVERNMENT | 2003-02-13 | — | — | US | disclosed |
| EP-1274401-A1 | STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING 7-SUBSTITUTED-3,5-DIHYDROXYHEPTANOIC ACIDS OR 7-SUBSTITUTED-3,5-DIHYDROXYHEPTENOIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-15 | — | — | EP | disclosed |
| EP-1272465-A2 | COMPOUNDS AND METHODS TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| CN-1379760-A | Process for the preparation of amorphous atorvastatin calcium | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2002-11-13 | — | — | CN | disclosed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| CN-1087288-C | Crystalline [R-(R',R')]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(5-methylethyl)-3-phenyl-4-(phenylamino) carbonyl]-1H-pyrole-1-heptanoic acid hemi calcium salt (atorvastatin) | WARNER LAMBERT CO (US) | 2002-07-10 | — | — | CN | disclosed |
| US-6403576-B1 | CHOLESTEROL SYNTHESIS INHIBITOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-06-11 | — | — | US | disclosed |
| US-20020016364-A1 | Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality | CRABTREE ACQUISITION CO, LLC | 2002-02-07 | — | — | US | disclosed |
| WO-2001077072-A2 | COMPOUNDS AND METHODS TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001076566-A1 | STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING 7-SUBSTITUTED-3,5-DIHYDROXYHEPTANOIC ACIDS OR 7-SUBSTITUTED-3,5-DIHYDROXYHEPTENOIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-10-18 | — | — | WO | disclosed |
| EP-0839132-A1 | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1) | WARNER-LAMBERT COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5618964-A | Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| US-5610314-A | Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1997003960-A1 | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1) | WARNER-LAMBERT COMPANY (US) | 1997-02-06 | — | — | WO | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| CN-1130188-A | Salt of phosphonocarboxyl sulfonate zoomaricoene synthetic inhibitor and method | BRISTOL MYERS SKIP CO (US) | 1996-09-04 | — | — | CN | disclosed |
| US-5543542-A | REACTING PHOSPHONOSULFONATE WITH OXIDIZING AGENT, REACTING PRODUCT WITH HYDROXYLAMINE PROTECTING AGENT, THEN WITH SILYL BROMIDE OR IODIDE | LAWRENCE R MICHAEL (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0710665-A1 | Phosphonosulfonate squalene synthetase inhibitor salts and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-05-08 | — | — | EP | disclosed |
| EP-0698609-A1 | Alpha-phosphorus substituted sulfinate derivatives as squalene synthetase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-02-28 | — | — | EP | disclosed |
| EP-0687263-A1 | NOVEL PROCESS FOR -i(TRANS)-6- 2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS | WARNER LAMBERT CO (US) | 1995-12-20 | — | — | EP | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| US-5447922-A | Anticholesterol agents and enzyme inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-09-05 | — | — | US | disclosed |
| CN-1089614-A | Alpha-phosphonosulfonate squalene synthetase inhibitors and method | SQUIBB & SONS INC (US) | 1994-07-20 | — | — | CN | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0409281-A1 | (R-(R*R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)-carbonyl)-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof | WARNER-LAMBERT COMPANY (US) | 1991-01-23 | — | — | EP | disclosed |
| EP-0247633-A1 | Trans-6-[2-(3- or 4-Carboxamido-substituted pyrrol-1-yl)-alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1987-12-02 | — | — | EP | disclosed |
| EP-0247633-A1 | Trans-6-[2-(3- or 4-Carboxamido-substituted pyrrol-1-yl)-alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (34 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079713-A1 | Novel salt forms of poorly soluble probucol esters and ethers | SLC10A1, SLC10A2, CEL | TBXAS1 1409/4885LMNA 1915/4885TSHR 1336/4885 |
| US-20120039980-A1 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ILK, FN1, COL1A1 | TBXAS1 609/4885LMNA 865/4885TSHR 4657/4885 |
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | COL2A1, FN1, TNNC1 | TBXAS1 1192/4885LMNA 1072/4885TSHR 1244/4885 |
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | CD44, SELP, EPCAM | TBXAS1 2537/4885LMNA 3608/4885TSHR 1640/4885 |
| US-20050065121-A1 | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters | HDLBP, CETP, APOB | TBXAS1 3935/4885LMNA 564/4885TSHR 1532/4885 |
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | TBXAS1 2952/4885LMNA 3440/4885TSHR 3425/4885 |
| US-20050186244-A1 | Polymer compositions and methods for their use | COL2A1, COL14A1, COL1A1 | TBXAS1 1318/4885LMNA 821/4885TSHR 4699/4885 |
| US-20090171099-A1 | PROCESS FOR THE PRODUCTION OF AMORPHOUS ATORVASTATIN CALCIUM | HMGCR, CACYBP, SARAF | TBXAS1 1991/4885LMNA 2258/4885TSHR 4278/4885 |
| US-20050186245-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | TBXAS1 2952/4885LMNA 3440/4885TSHR 3425/4885 |
| US-20050186261-A1 | Compositions and methods for treating contracture | COL2A1, FN1, TNNC1 | TBXAS1 1192/4885LMNA 1072/4885TSHR 1244/4885 |
| US-20060084816-A1 | Process for the production of atorvastatin calcium | CACNA1H, CACNA1I, CACNA1G | TBXAS1 474/4885LMNA 2693/4885TSHR 1384/4885 |
| US-20050169961-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | TBXAS1 2952/4885LMNA 3440/4885TSHR 3425/4885 |
| US-20030064967-A1 | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters | HDLBP, CETP, APOB | TBXAS1 3935/4885LMNA 564/4885TSHR 1532/4885 |
| US-20050175665-A1 | In combination with antiscarring, antifibrotic, and antiinflammatory agents for preventing surgical adhesions, and cartilage loss; hypertrophic scars, keloids, arthritis, vascular disease; injection or topical administration | MMP1, COL2A1, MMP13 | TBXAS1 1521/4885LMNA 1694/4885TSHR 4490/4885 |
| US-20030181520-A1 | Methods of reversing and preventing cardiovascular pathologies | TNNT2, TNNI3, TNNC1 | TBXAS1 342/4885LMNA 283/4885TSHR 4197/4885 |
| US-20020016364-A1 | Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality | HDLBP, CETP, APOB | TBXAS1 3168/4885LMNA 519/4885TSHR 1366/4885 |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | MMP1, COL2A1, FN1 | TBXAS1 2505/4885LMNA 1905/4885TSHR 878/4885 |
| US-20120252905-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | PGF, VCAM1, COL14A1 | TBXAS1 579/4885LMNA 1945/4885TSHR 4499/4885 |
| US-20040266879-A1 | Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality | HDLBP, CETP, APOB | TBXAS1 3168/4885LMNA 519/4885TSHR 1366/4885 |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | MMP1, COL2A1, FN1 | TBXAS1 2505/4885LMNA 1905/4885TSHR 878/4885 |
| US-20050181977-A1 | Medical implants and anti-scarring agents | MMP1, VCP, TNNT2 | TBXAS1 2360/4885LMNA 2624/4885TSHR 3320/4885 |
| US-20040110803-A1 | Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels | HMGCR, LIPA, LIPC | TBXAS1 1140/4885LMNA 397/4885TSHR 3278/4885 |
| US-20050154374-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | TBXAS1 2952/4885LMNA 3440/4885TSHR 3425/4885 |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | TBXAS1 2400/4885LMNA 844/4885TSHR 4495/4885 |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | MMP1, CDKN1A, MKI67 | TBXAS1 2952/4885LMNA 3440/4885TSHR 3425/4885 |
| US-20030032578-A1 | Antifungal and antiparasitic compounds | PIGO, CAT, ERG28 | TBXAS1 1607/4885LMNA 3993/4885TSHR 3496/4885 |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | PGF, VCAM1, COL14A1 | TBXAS1 579/4885LMNA 1945/4885TSHR 4499/4885 |
| US-20050281883-A1 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ILK, FN1, MMP1 | TBXAS1 1229/4885LMNA 917/4885TSHR 4451/4885 |
| US-20050175703-A1 | Polymer compositions and methods for their use | COL2A1, COL14A1, COL1A1 | TBXAS1 1318/4885LMNA 821/4885TSHR 4699/4885 |
| US-20120052040-A1 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | COL2A1, COL14A1, COL1A1 | TBXAS1 1318/4885LMNA 821/4885TSHR 4699/4885 |
| US-20050186239-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | TBXAS1 2952/4885LMNA 3440/4885TSHR 3425/4885 |
| US-20060147492-A1 | Medical implants and anti-scarring agents | MMP1, VCP, TNNT2 | TBXAS1 2360/4885LMNA 2624/4885TSHR 3320/4885 |
| US-20040082807-A1 | Novel salt forms of poorly soluble probucol esters and ethers | SLC10A1, SLC10A2, CEL | TBXAS1 1469/4885LMNA 2110/4885TSHR 1363/4885 |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ILK, PLOD3, MMP1 | TBXAS1 2259/4885LMNA 1008/4885TSHR 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.